Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision: 63 days

Cancer Drug Resistance

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Articles

Most Recent | Most Viewed | Most Downloaded

Breast cancer cell resistance to hormonal and targeted therapeutics is correlated with the inactivation of the NR6A1 axis

Open Access Original Article DOI: 10.20517/cdr.2024.69 22 Nov 2024
Views: Downloads:
Download PDF

Mechanism of ferroptosis resistance in cancer cells

Open Access Review DOI: 10.20517/cdr.2024.127 19 Nov 2024
Views: Downloads:
Download PDF

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond

Open Access Review DOI: 10.20517/cdr.2024.103 19 Nov 2024
Views: Downloads:
Download PDF

Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity

Open Access Review DOI: 10.20517/cdr.2024.131 18 Nov 2024
Views: Downloads:
Download PDF

Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cells

Open Access Original Article DOI: 10.20517/cdr.2024.101 15 Nov 2024
Views: Downloads:
Download PDF

Venetoclax resistance: mechanistic insights and future strategies

Open Access Review DOI: 10.20517/cdr.2021.125 5 May 2022
Views: Downloads:
Download PDF

Improving HER2 testing reproducibility in HER2-low breast cancer

Open Access Opinion DOI: 10.20517/cdr.2022.29 31 Aug 2022
Views: Downloads:
Download PDF

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

Open Access Review DOI: 10.20517/cdr.2022.20 1 Aug 2022
Views: Downloads:
Download PDF

Submission Deadline: 20 Apr 2025

Published articles: 0

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
The journal Cancer Drug Resistance has established a media partnership with the European Molecular Biology Laboratory (EMBL) for the upcoming EMBL Symposium - Mechanisms of drug resistance and tolerance in bacteria, fungi, and cancer.
On November 4, 2024, the editorial team sat down with Prof. David A. Gewirtz, a leading scientist in oncology research and an esteemed member of the journal’s Editorial Board.
On September 16, 2024, Stanford University and Elsevier jointly released the list of the world’s top 2% scientists.
We are pleased to announce that our journal, Cancer Drug Resistance (CDR), has obtained a new Impact Factor 2023 of 4.6, as reported by the Journal Citation Reports (JCR) released by Clarivate Analytics on June 20, 2024.
placing the journal in Q1 in the Pharmacology (medical) discipline

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Submission Deadline: 20 Apr 2025

Published articles: 0

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/